Fair quality of methodology was considered in studies that enrolled only male subjects (population category) [14, 22, 25, 26, 28] or when blood sampling did not coincide with a steady state of an investigated drug [13,14,15,16,17, 19, 24]
Despite advancements in ultra-fast and ultra-long-acting insulins, there has been a paucity of new non-insulin glucose-lowering therapies specifically licensed for type 1 diabetes
This deacetylates and modifies the activity of downstream SIRT1 targets (Cant et al., 2009)
Some patients may use both forms depending on their goals, but this should only be done with provider supervision
Open Access Macedonian Journal of Medical Sciences 2016, 4 (4), 636-640
Acknowledgements We would like to thank Lotte Bjerre Knudsen at Novo Nordisk for valuable discussions and provision of liraglutide and semaglutide